The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
Abstract
OBJECTIVE: To evaluate the efficacy and safety of 30, 50, and 70 mg/day lisdexamfetamine dimesylate compared with placebo in adults with attention-deficit/hyperactivity disorder (ADHD). METHOD: Following a 7- to 28-day washout, 420 adults aged 18 to 55 years with moderate to severe ADHD (DSM-IV-TR criteria) were treated with 30, 50, or 70 mg/day lisdexamfetamine or placebo, respectively, for 4 weeks (N = 119, 117, 122, and 62, respectively). The 50- and 70- mg/day groups underwent forced-dose titration. The primary efficacy measure was the clinician-determined ADHD Rating Scale (ADHD-RS) total score. The study was conducted from May 2006 to November 2006. RESULTS: Treatment groups were well matched at baseline, including in ADHD-RS scores. At endpoint, changes in ADHD-RS scores were significantly greater for each lisdexamfetamine dose than for placebo (placebo = -8.2, 30 mg/day lisdexamfetamine = -16.2, 50 mg/day lisdexamfetamine = -17.4, 70 mg/day lisdexamfetamine = -18.6; all p < .0001 vs. placebo), with no differences between doses. Significant differences relative to placebo were observed in each lisdexamfetamine group, beginning at week 1 and for each week throughout. The percentage of subjects who improved (Clinical Global Impressions-Improvement scale rating < or = 2) was significantly greater for each lisdexamfetamine dose than for placebo at each week and at endpoint (placebo = 29%, 30 mg/day lisdexamfetamine = 57%, 50 mg/day lisdexamfetamine = 62%, 70 mg/day lisdexamfetamine = 61%; all p < .01). Adverse events were generally mild and included dry mouth, decreased appetite, and insomnia. CONCLUSION: All 3 lisdexamfetamine doses were significantly more effective than placebo in the treatment of adults with ADHD, with improvements noted within 1 week. Lisdexamfetamine was generally well tolerated by these patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Discontinuations due to TEAEs with LDX in these studies (6.3% and 3.9%) are comparable to a published phase 2 study of LDX in BED (McElroy et al, 2015), to other clinical studies of LDX for which LDX is indicated (Adler et al, 2008; Wigal et al, 2010), and to other BED pharmacotherapy trials with other agents (Claudino et al, 2007; McElroy et al, 2003, 2007a, b).”
From Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials (2016) · cites this paper as Adler et al, 2008
In the citing paper
“The safety and tolerability profile of LDX observed regarding overall TEAEs, TEAEs leading to discontinuation, vital signs, and ECGs were consistent with published reports in adults with BED (McElroy et al, 2015) or attention-deficit/hyperactivity disorder (Adler et al, 2008; Wigal et al, 2010).”
From Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials (2016) · cites this paper as Adler et al, 2008
In the citing paper
“Lisdexamfetamine dimesylate is not metabolized by cytochrome P450 enzymes and unlikely to be involved in drug interactions involving CYP enzymes or P-glycoprotein; however, it is contraindicated during or within 2 weeks following the administration of monoamine oxidase inhibitors.”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [21]
In the citing paper
“in placebo-controlled LDX trials in ADHD, participants were considered treatment “responders” if they had a ≥ 30% reduction in ADHD symptoms using a standardized scale [27–29].”
From Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine (2024) · cites this paper as [27]
In the citing paper
“Improvements observed from LDX versus placebo in this trial were comparable to those observed in LDX interventions for adults with ADHD [16,27–29].”
From Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine (2024) · cites this paper as [27]
In the citing paper
“Previously reported abuse liability studies support the reduced abuse potential of LDX administered orally at doses ≤150 mg or intravenously at doses ≤50 mg, compared with d-amphetamine immediate-release 40 mg oral or 20 mg intravenous doses, respectively.21”
From Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder (2017) · cites this paper as [21]
In the citing paper
“An intention-to-treat analysis was applied in two studies.16,18”
From Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD (2014) · cites this paper as [16]
In the citing paper
“Unfortunately, only one study reported remission rates,16 and its pooled remission rate could not be calculated.”
From Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD (2014) · cites this paper as [16]
In the citing paper
“Although some randomized controlled trials (RCTs) of LDX demonstrated its efficacy and tolerability, compared with placebo, in the treatment of adult ADHD,16,18–21 they had a limited sample size.”
From Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD (2014) · cites this paper as [16]
In the citing paper
“The evidence suggests that LDX is an effective, safe, well-tolerated medication for children aged 6 to 12 years through to adulthood, with ADHD.16,17”
From Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD (2014) · cites this paper as [16]
In the citing paper
“Additionally, allocation concealment was reported in two trials18,21 and blinding of outcome assessment was reported in three trials.16,20,21”
From Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD (2014) · cites this paper as [16]
In the citing paper
“Six percent of subjects in the lisdexamfetamine group discontinued the drug owing to side effects, the most common being insomnia. Palpitations, hypertension, and dyspnea were also more common in the treatment group than in the placebo group.”
From Update on optimal use of lisdexamfetamine in the treatment of ADHD (2013) · cites this paper as [27]
In the citing paper
“In a randomized, placebo-controlled trial of 420 adult subjects with ADHD, Adler et al27 found statistically significant improvements in ADHD-RS-IV and CGI scores for all doses of lisdexamfetamine (30–50 mg) compared with placebo. These improvements were evident from the first week.”
From Update on optimal use of lisdexamfetamine in the treatment of ADHD (2013) · cites this paper as [27]
In the citing paper
“The common AEs in the current study, including decreased appetite, dry mouth, headache, and insomnia, are consistently seen in studies of long-acting stimulant medications administered to adults [12,18,35,36].”
In the citing paper
“LDX has demonstrated efficacy in reducing core ADHD symptoms in a randomized, controlled trial in adults [26], using the ADHD Rating Scale IV (ADHD-RS-IV) [27,28]”
In the citing paper
“The overall safety and tolerability findings observed in these studies are consistent with previously published studies of LDX augmentation for MDD with other clinical studies of LDX for which LDX is approved for use (Adler et al., 2008;Madhoo et al., 2014;McElroy et al., 2016;Trivedi et al., 2013Wigal et al., 2010).”
In the citing paper
“Multiple randomized, double-blind, placebo-controlled trials have shown LDX to be an effective treatment for children, adolescents and adults with ADHD, with a tolerability and safety profile consistent with the known effects of psychostimulant therapy [9–15].”
In the citing paper
“These results support previous placebo-controlled trials of LDX, which have demonstrated a robust treatment response in a range of patient groups [9, 11–13].”
In the citing paper
“Both therapies displayed safety profiles consistent with findings from previous studies [9, 11–13, 28–30].”
In the citing paper
“The most frequently reported TEAEs in the LDX treatment group (decreased appetite, decreased weight, headache, nausea and insomnia) and in patients receiving ATX (headache, nausea, somnolence, decreased appetite and fatigue) are consistent with findings from previous studies [9, 11–13, 28–30].”
Citations
Cites
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
(1976) · Medical Entomology and Zoology · Cited by 8,899
The worldwide prevalence of ADHD: a systematic review and metaregression analysis
Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.942 · Cited by 5,346
Self-citationKessler, R. C., Adler, L., Barkley, R., Biederman, J., Conners, C. K., Demler, O., Faraone, S. V., Greenhill, L. L., Howes, M. J., Secnik, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.716 · Cited by 3,886
Self-citation(1998) · Cited by 2,026
BARKLEY, R. A., FISCHER, M., EDELBROCK, C. S., & SMALLISH, L. (1990) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199007000-00007 · Cited by 1,507
Guy, W. L. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,441
General hospital psychiatry: the Italian experience.
Faraone, S. V., Sergeant, J. A., Gillberg, C., & Biederman, J. (2003) · Europe PMC (PubMed Central) · Cited by 1,277
Self-citationBarkley, R. A., Fischer, M., Smallish, L., & Fletcher, K. (2002) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.111.2.279 · Cited by 1,199
Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200202001-00003 · Cited by 927
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 217
Moss, S. B. (2009) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s4101 · Cited by 19
Murkett, K., Banaschewski, T., Lecendreux, M., Soutullo, C. A., Zuddas, A., Adeyi, B. A., Sorooshian, S., & Coghill, D. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s68273 · Cited by 21
Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate
Roesch, B. G., Corcoran, M. E., Fetterolf, J., Haffey, M. B., Martin, P. T., Preston, P. E., Purkayastha, J., Wang, P., & Ermer, J. C. (2013) · Drugs in R&D · doi:10.1007/s40268-013-0014-8 · Cited by 19
The use of lisdexamfetamine dimesylate for the treatment of ADHD
Childress, A. C., & Sallee, F. R. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.175 · Cited by 18
Waxmonsky, J. G., Waschbusch, D. A., Glatt, S. J., & Faraone, S. V. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m05979pur · Cited by 18
Effect Size of Lisdexamfetamine Dimesylate in Adults with Attention-Deficit/Hyperactivity Disorder
Wigal, T., Brams, M., Gasior, M., Gao, J., & Giblin, J. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.03.2275 · Cited by 17
Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder
Najib, J., Wimer, D., Zeng, J., Lam, K. W., Romanyak, N., Paige Morgan, E., & Thadavila, A. (2017) · Journal of Central Nervous System Disease · doi:10.1177/1179573517728090 · Cited by 17
Effectiveness and Duration of Effect of Open-Label Lisdexamfetamine Dimesylate in Adults With ADHD
Adler, L. A., Lynch, L. R., Shaw, D. M., Wallace, S. P., O’Donnell, K. E., Ciranni, M. A., Briggie, A. M., & Faraone, S. V. (2017) · Journal of Attention Disorders · doi:10.1177/1087054713485421 · Cited by 23
Self-citationMartin, P. T., Dirks, B., Gertsik, L., Walling, D. P., Stevenson, A., Corcoran, M., Raychaudhuri, A., & Ermer, J. C. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000205 · Cited by 17
Safety of Stimulants Across Patient Populations
Oliva, H. N. P., Prudente, T. P., Mayerson, T. F., Mignosa, M. M., Oliva, I. O., Potenza, M. N., Jegede, O. O., & Angarita, G. A. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.9492 · Cited by 23
The use of attention-deficit hyperactivity disorder medications in cardiac disease
Topriceanu, C., Moon, J., Captur, G., & Perera, B. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1020961 · Cited by 21
Weisler, R., Childress, A., Adler, L., Kollins, S., Goodman, D., Hamdani, & Dirks, B. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s47087 · Cited by 16
Self-citationErmer, J. C., Haffey, M. B., Richards, C., Lasseter, K. C., Roesch, B. G., Purkayastha, J., Corcoran, M., Harlin, B., & Martin, P. T. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0073-1 · Cited by 19
Martin, P. T., Corcoran, M., Zhang, P., & Katic, A. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-013-0156-z · Cited by 16
Pennick, M. (2013) · Journal of Drug Assessment · doi:10.3109/21556660.2013.775132 · Cited by 16
Why is ADHD so difficult to diagnose in older adults?
Goodman, D. W., Cortese, S., & Faraone, S. V. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2385932 · Cited by 17
Self-citationBrams, M., Giblin, J., Gasior, M., Gao, J., & Wigal, T. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.05.2288 · Cited by 15
Carton, L., Icick, R., Weibel, S., Demattéis, M., Kammerer, E., Batisse, A., & Rolland, B. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2112950 · Cited by 15
Waxmonsky, J. G., Waschbusch, D. A., Akinnusi, O., & Pelham, W. E. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0042 · Cited by 15
Siffel, C., Page, M. J., Maxwell, T., Thun, B., Kolb, N., Rosenlund, M., von Bredow, D., & Keja, J. (2020) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0173 · Cited by 15
Fridman, M., Hodgkins, P. S., Kahle, J. S., & Erder, M. H. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.01.001 · Cited by 16
Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD
Dew, R. E., & Kollins, S. H. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.531009 · Cited by 14
Self-citationBabcock, T., Dirks, B., Adeyi, B., & Scheckner, B. (2012) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-13-18 · Cited by 14
Scott, D. A., Gignac, M., Kronfli, R. N., Ocana, A., & Lorberg, G. W. (2015) · Journal of Correctional Health Care · doi:10.1177/1078345815618392 · Cited by 15
Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems
Mattingly, G., & Anderson, R. H. (2016) · CNS Spectrums · doi:10.1017/s1092852916000808 · Cited by 17
Richards, C., Iosifescu, D. V., Mago, R., Sarkis, E., Reynolds, J., Geibel, B., & Dauphin, M. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117722998 · Cited by 14
New Drugs to Treat ADHD: Opportunities and Challenges in Research and Development
Heal, D. J., Gosden, J., & Smith, S. L. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_332 · Cited by 16
Wigal, T. L., Childress, A. C., Frick, G. S., Yan, B. M., Wigal, S. B., & Madhoo, M. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2018.1389227 · Cited by 14
Brown, T. E., Chen, J., & Robertson, B. (2020) · Journal of Attention Disorders · doi:10.1177/1087054720961819 · Cited by 15
Lisdexamfetamine Dimesylate: In Attention-Deficit Hyperactivity Disorder in Adults
Weber, J., & Siddiqui, M. A. A. (2009) · CNS Drugs · doi:10.2165/00023210-200923050-00005 · Cited by 13
Zimovetz, E. A., Joseph, A., Ayyagari, R., & Mauskopf, J. A. (2018) · The European Journal of Health Economics · doi:10.1007/s10198-016-0864-4 · Cited by 13
Update on adult attention-deficit/hyperactivity disorder
Hammerness, P. G., Surman, C. B. H., & Miller, K. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0077-z · Cited by 12
Development of the Korean Practice Parameter for Adult Attention-Deficit/Hyperactivity Disorder
Bahn, G. H., Lee, Y. S., Yoo, H. K., Kim, E., Park, S., Han, D. H., Hong, M., Kim, B., Lee, S. I., Bhang, S., et al. (2019) · Journal of korean Academy of Child and Adolescent Psychiatry · doi:10.5765/jkacap.190030 · Cited by 14
Giacobbe, P., Rakita, U., Lam, R. W. M., Milev, R. V., Kennedy, S. H., & McIntyre, R. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.09.041 · Cited by 12
Wigal, S. B., López, F. A., Frick, G. S., Yan, B. M., Robertson, B., & Madhoo, M. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1574402 · Cited by 13
Martínez-Raga, J., Knecht, C., de Alvaro, R., Szerman, N., & Ruiz, P. (2012) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0b013e318277060c · Cited by 12
Perioperative Considerations for Patients Exposed to Psychostimulants
Emerick, T. D., Martin, T. J., & Ririe, D. G. (2023) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006303 · Cited by 15
Pharmacotherapy of ADHD in adults
Prince, J. B., Morrison, N. R., & Wilens, T. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139035491.023 · Cited by 11
Cardiovascular Effects of Drugs Used to Treat Attention-Deficit/Hyperactivity Disorder
Fay, T. B., & Alpert, M. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000233 · Cited by 11
Treatment with stimulants and the risk of COVID-19 complications in adults with ADHD
Tuan, W., Babinski, D. E., Rabago, D., & Zgierska, A. E. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.07.005 · Cited by 12
Schein, J. R., Cloutier, M., Gauthier‐Loiselle, M., Catillon, M., Xu, C., Chan, D., & Childress, A. C. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.6.528 · Cited by 11
Treating Attention-Deficit/Hyperactivity Disorder in Adults
Weisler, R. H., & Childress, A. C. (2011) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.11r01168 · Cited by 10
Self-citationAdler, L. A., Alperin, S., Leon, T., & Faraone, S. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.09.2796 · Cited by 10
Self-citationDose Response Effects of Lisdexamfetamine Dimesylate Treatment in Adults With ADHD
Faraone, S. V., Spencer, T. J., Kollins, S. H., Glatt, S. J., & Goodman, D. (2011) · Journal of Attention Disorders · doi:10.1177/1087054711403716 · Cited by 9
Self-citationErmer, J. C., Martin, P. T., Corcoran, M., & Matsuo, Y. (2019) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12082 · Cited by 9
Adler, L. A., Frick, G. S., & Yan, B. M. (2017) · Journal of Attention Disorders · doi:10.1177/1087054717696770 · Cited by 10
Self-citationDagistan, A. A., Gıca, Ş., Aydın, A., & Çilli, A. S. (2021) · Journal of Forensic Sciences · doi:10.1111/1556-4029.14894 · Cited by 8
Schein, J. R., Cloutier, M., Gauthier‐Loiselle, M., Catillon, M., Meng, Y., Libchaber, B., Jiang, F., & Childress, A. C. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s467724 · Cited by 9
Ermer, J. C., Corcoran, M., Lasseter, K. C., & Martin, P. T. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000343 · Cited by 8
Reliability and validity of the Time-Sensitive ADHD Symptom Scale in adults
Adler, L. A., Shaw, D. M., Spencer, T. J., Newcorn, J. H., Sitt, D. J., Morrill, M. I., Davidow, J. V., Glatt, S. J., & Faraone, S. V. (2011) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2010.12.002 · Cited by 8
Self-citationMetcalf, C. A., Page, C. E., Stocker, B. O. S., Johnson, R. L., Duffy, K. A., Sammel, M. D., Loughead, J., & Epperson, C. N. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.07.689 · Cited by 7
Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder
McDonagh, M. S., & Peterson, K. (2011) · Cited by 7
Hung, Y., Green, A., Kelberman, C., Gaillard, S. L., Capella, J., Rudberg, N., Gabrieli, J. D. E., Biederman, J., & Uchida, M. (2024) · Journal of Attention Disorders · doi:10.1177/10870547231222261 · Cited by 7
Self-citationThe use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders
Roncero, C., & Alvarez, E. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.932691 · Cited by 7
Lisdexamfetamine: A Prodrug Stimulant for ADHD
Howland, R. H. (2008) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20080801-05 · Cited by 7
A clinician’s guide for navigating the world of attention deficit hyperactivity disorder medications
Mattingly, G., & Young, J. (2021) · CNS Spectrums · doi:10.1017/s1092852921000146 · Cited by 5
Childress, A., Lloyd, E., Johnson, S. A., Gunawardhana, L., & Arnold, V. (2022) · Journal of child and adolescent psychopharmacology · doi:10.1089/cap.2021.0138 · Cited by 7
Dutta, C. N., Christov‐Moore, L., Ombao, H., & Douglas, P. K. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.938501 · Cited by 8
Cowles, B. J. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s6733 · Cited by 6
Reimherr, F. W., Gift, T. E., Steans, T. A., Reimherr, M. L., Rosenberg, L. I., Wilson, M., & Marchant, B. K. (2022) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001592 · Cited by 6
Citrome, L., Kando, J. C., & Bliss, C. A. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s158395 · Cited by 6
Assessment and Treatment of ADHD in People Over 60
Kooij, J. J. S., Bijlenga, D., & Michielsen, M. (2019) · The ADHD Report · doi:10.1521/adhd.2019.27.4.1 · Cited by 6
Pliszka, S. R. (2012) · Wiley eBooks · doi:10.1002/9781119958338.ch6 · Cited by 5
van Stralen, J., Parhar, G., Parhar, A., Tourjman, V., Khattak, S., Ahmed, T., Donnelly, G. A. E., & Ratz, J. D. (2023) · Journal of Attention Disorders · doi:10.1177/10870547231172767 · Cited by 4
Schein, J. R., Cloutier, M., Gauthier‐Loiselle, M., Catillon, M., Xu, C., Qu, A., Lee, F., & Childress, A. C. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2024-0089 · Cited by 6
Wang, Y., Yu, M., Yan, B. M., Martin, P. T., & Robertson, B. (2019) · Drugs in R&D · doi:10.1007/s40268-019-0267-y · Cited by 4
Childress, A. C., & Burton, S. M. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2103406 · Cited by 4
Heal, D. J., Gosden, J., & Smith, S. L. (2023) · Advances in pharmacology · doi:10.1016/bs.apha.2023.10.002 · Cited by 4
Armanious, A. J., Asare, A., Mitchison, D., & James, M. H. (2024) · Psychiatry Research Communications · doi:10.1016/j.psycom.2024.100195 · Cited by 4
Babinski, D. E., Waxmonsky, J. G., Waschbusch, D. A., Humphery, H., & Pelham, W. E. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0129 · Cited by 4
Adler, L. A., Robertson, B., Chen, J., & Sarkis, E. H. (2020) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2020.0012 · Cited by 4
Self-citationForns, J., Dudukina, E., Hägg, D., Szentkúti, P., Gembert, K., Plana, E., Gilsenan, A., Horváth–Puhó, E., Ehrenstein, V., Reutfors, J., et al. (2022) · Neurology and Therapy · doi:10.1007/s40120-022-00396-y · Cited by 3
Weisler, R. H., Babcock, T., Adeyi, B., & Brams, M. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.09.2798 · Cited by 2
Self-citationHonorato, G. S., de Morais, R. B. A. R., de França, W. C., Borba, C. V. F. D., Versa, L. C., Pinheiro, T. K. B., Paulo, C. H. R. D., & Peixoto, J. O. B. (2024) · Cuadernos de Educación y Desarrollo · doi:10.55905/cuadv16n2-093 · Cited by 2
Schein, J. R., Cloutier, M., Bungay, R., Gauthier‐Loiselle, M., & Childress, A. C. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2342749 · Cited by 2
Rutledge-Jukes, H., Jonnalagadda, P., McIntosh, A. P., Krstovski, S., Andriani, N. T., Smith, I. R., Prendergast, L., & Lynch, J. M. (2024) · Cureus · doi:10.7759/cureus.68324 · Cited by 5
Schein, J. R., Cloutier, M., Gauthier‐Loiselle, M., Catillon, M., Meng, Y., Libchaber, B., Jiang, F., & Childress, A. C. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00681-y · Cited by 2
Effect of amphetamines on blood pressure
Chan, M., Chan, J. J., & Wright, J. M. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007896.pub4 · Cited by 6
Fricke, U., Hein, L., & Schwabe, U. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_2 · Cited by 2
Harris, S. (2017) · Journal of International Crisis and Risk Communication Research · Cited by 2
(2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.2064 · Cited by 2
Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung ADHS) im Erwachsenenalter
Alm, B., & Sobanski, E. (2008) · Springer eBooks · doi:10.1007/978-3-540-33129-2_64 · Cited by 2
A META-ANALYSIS OF PRESCRIPTION STIMULANT EFFICACY: ARE STIMULANTS NEUROCOGNITIVE ENHANCERS?
Marraccini, M. E. (2015) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/diss-marraccini-marisa-2015 · Cited by 2
Attention deficit hyperactivity disorder in prison inmates
Ginsberg, Y. (2012) · Figshare · Cited by 2
Lisdexamfetamine dimesylate: a guide to its use in attention-deficit hyperactivity disorder
&NA; (2010) · Drugs & Therapy Perspectives · doi:10.2165/11205310-000000000-00000 · Cited by 2
Therapeutic Use of Dopamine Enhancers (Stimulants)
Zuddas, A., & Carucci, S. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_138-1 · Cited by 1
Tuan, W., Sarkar, N., Griffin, P. M., & Babinski, D. E. (2026) · Psychiatric Research and Clinical Practice · doi:10.1176/appi.prcp.20250149 · Cited by 1
Clinical Utility of Lisdexamfetamine for the Management of Attention-Deficit Hyperactivity Disorder
Nguyen, M. L., Shapiro, M. A., & Tharani, S. (2012) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s8706 · Cited by 1
Once-daily medications for the pharmacological management of ADHD in adults
Tcheremissine, O. V. (2009) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s4206 · Cited by 1
Richards, C., Iosifescu, D. V., Mago, R., Sarkis, E. H., Geibel, B., Dauphin, M., McIntyre, R. S., Weisler, R. H., Brawman‐Mintzer, O., Gu, J., et al. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000897 · Cited by 1
Self-citationLisdexamfetamine: Stimulant Prodrug for ADHD in Children and Adults
Chauhan, M., Bestha, D. P., & Madaan, V. (2010) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s1077 · Cited by 1
Experiencia en la utilización de lisdexanfetamina en el manejo del TDAH de niños y adolescentes
Russi, M. (2018) · Revista de Psiquiatría Infanto-Juvenil · doi:10.31766/revpsij.v35n3a2 · Cited by 1
Efficacy of Amphetamines, Methylphenidate, and Modafinil in the Treatment of Mental Disorders
Retz, W. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_319 · Cited by 1
ADHD, psychostimulants, and sleep disorders: Is there a link?
Mattingly, G. W. (2009) · Current Attention Disorders Reports · doi:10.1007/s12618-009-0013-4 · Cited by 1
Childress, A. C. (2010) · Wiley eBooks · doi:10.1002/9780470749180.ch13
Surman, C. B. H., Hammerness, P. G., & Miller, K. (2009) · Current Attention Disorders Reports · doi:10.1007/s12618-009-0018-z
Wigal, T. L., Brams, M. N., Gasior, M., Gao, J., Squires, L. A., & Giblin, J. M. (2010)
Review of Long-Acting Stimulant and Nonstimulant ADHD Pharmacotherapy in Canada
Weiss, M. D., Childress, A. C., Pucci, M. L., & Hechtman, L. T. (2010)
Alamir, A. M. (2018) · Lu Zone Ul (Laurentian University)
BaniFatemi, S. (2019) · uO Research (University of Ottawa) · doi:10.20381/ruor-22928
Metadata
- Authors
- Adler, L. A., Goodman, D. W., Kollins, S. H., Weisler, R. H., Krishnan, S., Zhang, Y., & Biederman, J.
- Affiliations
- NYU Langone Health (US)
- Duke University (US)
- University of North Carolina at Chapel Hill (US)
- Harvard University (US)
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2008-09-30
- Volume
- 69
- Issue
- 9
- Pages
- 1364-1373
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1979206088
- Cited by
- 218
- References
- 28
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 14 · 2023: 5 · 2022: 12 · 2021: 5 · 2020: 5 · 2019: 6 · 2018: 10 · 2017: 16 · 2016: 9 · 2015: 9 · 2014: 19 · 2013: 22 · 2012: 14
- FWCI
- 15.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- lisdexamfetamine dimesylate, adult ADHD, ADHD medication, dose comparison, ADHD Rating Scale, adverse events, stimulant efficacy, xerostomia, appetite loss, insomnia, placebo response, washout period
- MeSH terms
- Lisdexamfetamine Dimesylate, Adolescent, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Dextroamphetamine, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Personality Assessment, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
